Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
Date:4/23/2009

NEW YORK, April 23 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced the appointment of Michael P. Tarnok to be its interim Chairman and Chief Executive Officer, replacing Michael S. Weiss, effective immediately.

Mr. Tarnok, age 54, has served on Keryx's Board of Directors since September 2007. Mr. Tarnok spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director -- US Manufacturing. From 2000-2007, Mr. Tarnok served as Senior Vice President, Finance in Pfizer's US Pharmaceuticals Division. In this position, Mr. Tarnok handled all finance responsibilities for the division, including contracting, trade management, forecasting of significant product launches and Sarbanes-Oxley compliance. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex is currently in Phase 2 clinical development for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, or ESRD. The Company is also developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that modulates Akt, a protein in the body associated with tumor survival and growth. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types. The Company also has an in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

    KERYX CONTACT:
        Lauren Fischer
        Director - Investor Relations
        Keryx Biopharmaceuticals, Inc.
        Tel: 212.531.5965
        E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... a new moving magnet Voice Coil Actuator with a flexure design that ensures ... long life with cost-effective pricing and is ideally suited where extreme precision is ...
(Date:11/30/2016)... 2016  The Allen Institute for Cell Science ... publicly available collection of gene edited, fluorescently tagged ... cellular structures with unprecedented clarity. Distributed through the ... are a crucial first step toward visualizing the ... makes human cells healthy and what goes wrong ...
(Date:11/30/2016)... 2016 Part of 5m$ Investment in ... ... Aptuit, LLC today announced that it had successfully completed the ... compounds have increased the Screening Collection to over 400,000. The ... capabilities of the company. This expansion, complemented by new robotics ...
(Date:11/30/2016)... ... November 30, 2016 , ... On 28 November 2016, the International Union of ... nihonium (Nh), moscovium (Mc), tennessine (Ts), and oganesson (Og), respectively for element 113, 115, ... proposed by the discoverers have been approved by the IUPAC Bureau. The IUPAC Council ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016 Research and Markets has announced ... 2021" report to their offering. ... ... by 2021 from USD 6.21 Billion in 2016, growing at a ... of the bioinformatics market is driven by the growing demand for ...
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/22/2016)... , June 22, 2016 On Monday, the ... to industry to share solutions for the Biometric Exit ... Customs and Border Protection (CBP), explains that CBP intends ... departing the United States , in ... to defeat imposters. Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
Breaking Biology News(10 mins):